Liquid Biopsy IVD Market Size, Share, Growth, and Industry Analysis, By Type (Circulating Tumor Cells, Circulating Tumor DNA, Extracellular Vesicles, and Others), By Application (Blood Sample Based, Urine Sample Based, and Other Bio Fluids Based), Regional Insight, and Forecast To 2033

• 

   Request a Free Sample To Get More Information on this Market

LIQUID BIOPSY IVD MARKET REPORT OVERVIEW

Global Liquid Biopsy IVD Market size was projected at USD 5.53 billion in 2024 and is anticipated to reach USD 13.26 billion by 2033, registering a CAGR of 10.5% during the forecast period.

Liquid biopsy In vitro diagnostics (IVD) is a game-changing medical approach that is accomplished by assessing biological fluids, mainly blood, to uncover early signs of several diseases, in this case, cancer. Unlike in the case of the normal tissue biopsies that are commonly represented by surgical removal of tissue samples, liquid biopsy, considered non-invasive or minimally invasive testing, stands distinctive in that it is much safer and more comfortable for patients.

COVID-19 IMPACT

"Market Growth restrained by Pandemic due to Delay in routine screening and diagnosis"

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

Coronavirus has created problems in the road of health care as well; one of them is delayed or skipped cancer detection programs, and diagnostic techniques. Consequently, patients have experienced a delay in getting animal Cancer in the period until clinics open again if the demand for liquid biopsy services rises.

LATEST TRENDS

"Advancements in technology to Drive Market Growth"

One of the most important elements in Molecular Biology techniques, which are getting improved by day with the use of techniques such as NGS, digital PCR, and microfluidics, is their sensitivity, specificity, and accuracy of liquid biopsy tests. These technical developments are beginning to make it possible to find the discrete mutations and different biomarkers in the circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other analytes with greater accuracy to be discovered. Continuing research and development are addressing the areas of increasing the sensitivity and targeted Ness of Liquid Biopsy assays. This includes making molecular biology techniques such as next-generation sequencing (NGS) and digital PCR resident-based and drop-based, consequently allowing to location of rare mutations and biomarkers in the low quantities in biofluids.

LIQUID BIOPSY IVD MARKET SEGMENTATION

By Type

Based on type the global market can be categorized into Circulating Tumor Cells, Circulating Tumor DNA, Extracellular Vesicles, and Others.

• Circulating Tumor Cells- CTC stands for Cancerous Cell Cycle which is a specific type of cancer cells that have broken off from the primary places of tumors or metastatic sites and have entered the blood circulatory system. Isolating and assessing CTCs allows both the detection of and the characterization of tumor cells in situ, which in return reveals the complexity of tumor variations and metastatic potential.

• Circulating Tumor DNA- also known as ctDNA, is tumor DNA that has been broken into pieces from apoptosis, necrosis, or active release from tumor cells into the bloodstream. From ctDNA analysis, tumor-exclusive mutations, CNA (copy number abnormalities), and other genetic defects contained in the tumor genome can be detected.

• Extracellular Vesicles- EVs include the tiny membrane-bound vesicles that are released by the transmembrane cells mainly during malignancies. Cancer cells shed biomolecules containing proteins, RNA, DNA, and lipids, packaging them into extracellular vesicles and the majority of components resemble the tumor itself.

By Application

Based on application the global market can be categorized into Blood Sample Based, Urine Sample Based, and Other Bio Fluids Based.

• Blood Sample Based- Circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) are identified in the bloodstream with liquid biopsy of blood samples. Liquid biopsy also screens these biomarkers through blood as well as other body fluids.

• Urine Sample Based- Liquid biopsy, using urine samples, can seize shedding structured by bladder tumors in the urinary tract. Thanks to this shed, tumor misses DNA and RNA. The sample of the urine is a less painful (but also a more non-invasive) option for bladder cancer surveillance. The urine-based liquid biopsy, will serve as a valuable complement to other diagnostic modalities, such as cystoscopy and urine cytology.

• Other Biofuels Based - Liquid biopsy assays in CSF are a form of CNS cancer and metastases-related tests, because they have permits to those processes, compared with other body fluids. CSF-based liquid biopsy offers a chance for physicians to define the tumor genetics and choose what treatment to administer according to specific molecular alterations present in the brain cancer patient.

DRIVING FACTORS

"Early cancer detection and monitoring to Boost the Market"

One of the key driving factors in the global Liquid Biopsy IVD market growth is Early cancer detection and monitoring. ctDNA (circulating tumor DNA), CTCs (circulating tumor cells), and other biomarkers can be identified in the examination of biological fluids by liquid biopsy. Through this, cancer detection is done at the early stages and the disease is monitored. Early diagnosis is a key to late-stage disease management. It enables healthcare consumers to be treated sooner, leads to improved outcomes, and reduces healthcare costs. The ability to detect cancer early means that treatment can start promptly and effectively, thereby helping patients achieve better health outcomes, such as increased survival and decent quality of life. It guarantees a non-invasive and more feasible way of detecting ctDNA circulating and other biomarkers in the biological fluid, in the process which leads to diagnosing cancer earlier when treatment becomes also more effective.

"Rising prevalence of cancer to Expand the Market"

Another driving factor in the global Liquid Biopsy IVD market is the Rising prevalence of cancer. The global expansion of cancer is doing so because the populations are demanding reliable diagnostic methods in order to detect, monitor, and care for the condition at early stages. Liquid biopsy enables to obtain a sensitive tissue sample with almost no invasion, which is really vital for cancer detection and monitoring since the necessity for exact diagnosis and quick decision-making is getting bigger. In the present age, a continued increase in cancer cases all over the globe has made it very essential to have excellent detection tools, which can enable the disease to be detected at an early stage when treatment can have a high success rate. Liquid ctDNA biopsy is a non-invasive way of identifying cells, that have lost their normal gene expression, hence, providing an early detection and allergy intervention.

RESTRAINING FACTORS

"Cost considerations and Reimbursement challenges to Potentially Impede Market Growth"

One of the key restraining factors in the global Liquid Biopsy IVD market is Cost Considerations and Reimbursement Challenges. In liquid biopsy tests costs could turn out to be more than compared to traditional diagnostic methods which might limit their application, foremostly in countries with low healthcare budgets with hardly any reimbursement coverage. Cost-effectiveness studies shall be prepared and reducing the price of liquid biopsy assays is the solution to this obstacle. Different insurance companies have different reimbursement frameworks, which may create difficulties in getting reimbursed for liquid biopsy tests. If the insurance coverage is eventually insufficient or the wait for approval is very long, this can affect the market acceptance negatively and reduce the accessibility of tests using liquid biopsy for the patients.

• 

   Request a Free Sample To Get Analysis on Major Geographic Market

LIQUID BIOPSY IVD MARKET REGIONAL INSIGHTS

"North America Region Dominating the Market Due to Advanced Healthcare Infrastructure."

The market is primarily segregated into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa.

North America has emerged as the most dominant region in the global Liquid Biopsy IVD market share due to several factors. North America, the United States in particular, is equipped with a well-established healthcare infrastructure having the availability of advanced laboratory facilities, efficient regulatory schemes, and a high health expenditure. These factors tend to be strong drivers of the clinical uptake and commercialization of innovative diagnostic tools such as liquid biopsy.

KEY INDUSTRY PLAYERS

"Key Industry Players Shaping the Market through Innovation and Market Expansion"

The Liquid Biopsy IVD market is significantly influenced by key industry players that play a pivotal role in driving market dynamics and shaping consumer preferences. These key players possess extensive retail networks and online platforms, providing consumers with easy access to a wide variety of Liquid Biopsy IVD options. Their strong global presence and brand recognition have contributed to increased consumer trust and loyalty, driving product adoption. Moreover, these industry giants continually invest in research and development, introducing innovative designs, materials, and smart features in Liquid Biopsy IVD, catering to evolving consumer needs and preferences. The collective efforts of these major players significantly impact the competitive landscape and future trajectory of the market.

List of Top Liquid Biopsy IVD Companies

• Bio-Rad (U.S.)
• Roche (Switzerland)
• Biocartis (Belgium)
• Qiagen (Germany)
• Guardant Health (U.S.)

INDUSTRIAL DEVELOPMENT

January 2023: QIAGEN declared the CE-IVD marking and commercial rollout of their diagnostic platform EZ2 connect MDx being Automated and used to Process Samples in Laboratories.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The research report delves into market segmentation, utilizing both qualitative and quantitative research methods to provide a thorough analysis. It also evaluates the impact of financial and strategic perspectives on the market. Furthermore, the report presents national and regional assessments, considering the dominant forces of supply and demand that influence market growth. The competitive landscape is meticulously detailed, including market shares of significant competitors. The report incorporates novel research methodologies and player strategies tailored for the anticipated timeframe. Overall, it offers valuable and comprehensive insights into the market dynamics in a formal and easily understandable manner.